novel oral polio vaccine type 3 (nopv3)
Vaccineexperimental
Clinical trial activity
3 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2021 (NCT04529538)
Timeline
Indications
Studied for
Mechanism of action
- PoliovirusImmunity, active
immunity, active - poliovirus
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06137664 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2023 | PATH |
| NCT05654467 | Phase 2 | May 29, 2023 | Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), Cevaxin, PATH, PT Bio Farma, Technical Resources International, Inc. (TRI) |
| NCT04529538 | Phase 1 | Jan 31, 2021 | Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), Dartmouth University, PATH, The EMMES Corporation, University of North Carolina at Chapel Hill, University of Vermont, Viroclinics Biosciences B.V. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PATH | Academic/Hospital | 3 | 3 | 2 | 2021 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Centers for Disease Control and Prevention (CDC) | Government | 2 | 0 | 2 | 2021 |
| Cevaxin | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Dartmouth University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| PT Bio Farma | For profit | 1 | 0 | 1 | 2023 |
| Technical Resources International, Inc. (TRI) | For profit | 1 | 0 | 1 | 2023 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2021 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Vermont | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Viroclinics Biosciences B.V. | For profit | 1 | 0 | 1 | 2021 |
11 organizations
Page 1 / 1